Skip to main content
S&P 5007,743.41+0.51%DOW51,828.62+0.93%NASDAQ27,068.72+0.48%BTC$83,896.00-0.86%ETH$2,687.00-0.12%GOLD$4,320.50+0.52%OIL$92.44-2.29%
Smart Investors Daily
VI

NASDAQ · VIVS

VivoSim Labs, Inc.

Healthcare · Biotechnology

$0.22

Down-$0.00 (-0.62%)

Updated Sep 26, 2026, 12:22 PM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
5.82M
P/E ratio
-2.81
Dividend yield
0.00%
52-week range
$0.22 – $1.96
Volume
260.03K
Avg. volume
510.14K

Price performance

VIVS price history

1M range · 20 trading sessions · Daily adjusted prices

VIVS closed at $0.22 after 20 trading sessions, down 21.49% for the selected period.

Last close
$0.22
Period change
-21.49%
Period low
$0.22
Period high
$0.30
Daily close
View OHLC price history
VIVS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 25, 2026$0.2252$0.2294$0.2208$0.224260.03K
Sep 24, 2026$0.226$0.2329$0.2204$0.2254559.3K
Sep 23, 2026$0.2376$0.2421$0.2221$0.2291624.87K
Sep 22, 2026$0.2504$0.259$0.232$0.23531.24M
Sep 21, 2026$0.2284$0.264$0.224$0.24831.46M
Sep 18, 2026$0.2594$0.264$0.2167$0.2271.57M
Sep 17, 2026$0.2667$0.2701$0.256$0.2591597.84K
Sep 16, 2026$0.27$0.2721$0.245$0.26216.39M
Sep 15, 2026$0.276$0.2815$0.272$0.2725304.67K
Sep 14, 2026$0.293$0.293$0.272$0.2811391.57K
Sep 11, 2026$0.30$0.30$0.2805$0.2831419.93K
Sep 10, 2026$0.2755$0.3019$0.2732$0.29981.4M
Sep 9, 2026$0.282$0.2893$0.2723$0.275398.23K
Sep 8, 2026$0.283$0.2861$0.2724$0.2817697.57K
Sep 4, 2026$0.2824$0.284$0.2753$0.2782268.05K
Sep 3, 2026$0.2755$0.2835$0.272$0.279613.95K
Sep 2, 2026$0.275$0.282$0.271$0.2798386.56K
Sep 1, 2026$0.295$0.2959$0.2736$0.2787370.86K
Aug 31, 2026$0.29$0.2916$0.2767$0.2914358.76K
Aug 28, 2026$0.293$0.2976$0.285$0.2853237.68K

Latest VIVS news

The latest Smart Investors Daily articles mentioning VIVS.

Stock researchCompany · Overview

VIVS research

Overview

Company profile and research snapshot.

Company profile

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 16, 2026

VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs

New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalitiesSAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ: VIVS) (“VivoSim” or the “Company”) unveils new clinical benchmark data at the 58th Congress of the European Societies of Toxicology (EUROTOX 2026) in Vienna, Austria, demonstrating the ability of its NAMkind™ 3D human liver and intestin

Yahoo · Sep 1, 2026

VivoSim Labs to Add Rat Liver Model to NAMkind Platform

New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humansSAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced plans to develop a rat liver model that will complement its existing NAMkind™ human liver platform and expand the Company’s liv

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By